Related Experiment Video

Updated: Aug 11, 2026

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries
09:39

A Platform of Anti-biofilm Assays Suited to the Exploration of Natural Compound Libraries

Published on: December 27, 2016

Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity

A Dalhoff1, C Krasemann, S Wegener

  • 1Research and Development Centre, Bayer AG, Pharma Research Center Wuppertal, PH-PD SDD AI, Building 402, Aprather Weg 18, D-42113 Wuppertal, Germany. axel.dalhoff.ad@bayer-ag.de

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|March 16, 2001
PubMed

Insights

Moxifloxacin effectively combats Streptococcus pneumoniae, a common cause of respiratory infections. This new fluoroquinolone shows consistent activity against various strains, including those resistant to penicillin.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Streptococcus pneumoniae is a major cause of bacterial respiratory tract infections.
  • Increasing antimicrobial resistance in S. pneumoniae necessitates novel therapeutic agents.
  • Fluoroquinolones are a class of antibiotics used to treat bacterial infections.

Purpose of the Study:

  • To evaluate the efficacy of moxifloxacin against Streptococcus pneumoniae.
  • To assess moxifloxacin's activity across different penicillin susceptibility profiles of S. pneumoniae.

Main Methods:

  • Review of preclinical data on moxifloxacin.
  • Analysis of available clinical experience with moxifloxacin.
  • Testing moxifloxacin against penicillin-sensitive and resistant S. pneumoniae strains.

Main Results:

  • Moxifloxacin demonstrated potent activity against S. pneumoniae in preclinical studies.
  • Clinical data supported moxifloxacin's effectiveness in treating pneumococcal infections.
  • Activity was observed irrespective of the strain's penicillin susceptibility.

Conclusions:

  • Moxifloxacin is a promising antibacterial agent for treating infections caused by Streptococcus pneumoniae.
  • Its efficacy against penicillin-resistant strains makes it a valuable therapeutic option.
  • Moxifloxacin offers a reliable treatment for pneumococcal infections in the face of rising resistance.

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...